The Food and Drug Administration (FDA) has introduced a new program called ‘FDA PreCheck’ to help strengthen U.S. drug production. This initiative aims to make it easier and faster to build new pharmaceutical factories in the country. The FDA says this program will help reduce America’s dependence on foreign-made drugs and ensure a more reliable supply of medicines. FDA Commissioner Martin Makary explained that this is one of many steps the agency is taking to improve the U.S. drug supply chain. The announcement comes as the Trump administration has threatened to impose high tariffs on imported drugs. President Trump recently said he plans to start with a small tariff but could increase it to 250% over the next year and a half. Many drug companies are already investing billions of dollars to build new factories in the U.S., which would help shift the supply chain. However, building new drug factories can take years, so these investments won’t have an immediate impact. Currently, more than half of the medicines used in the U.S. are made overseas, and the country relies heavily on foreign suppliers for key ingredients in drugs. The FDA’s new program will involve more frequent communication with drugmakers during the planning and construction phases of new factories. It will also encourage companies to prepare detailed records of their facilities, which can be used in future drug applications. The FDA will hold a public meeting on September 30 to discuss the program in more detail.